Home » Newsletters » BioWorld Science

BioWorld Science

April 6, 1999

View Archived Issues

Nycomed Amersham: year-end 1998 highlights

Shire: year-end 1998 highlights

Bioniche enters supply agreement with Sanova for Suplasyn

Antisoma's Theragyn granted orphan drug status in the U.S.

Novel furansulfonic acid compounds for neurodegenerative, autoimmune and inflammatory disorders

Roche presents new metabotropic glutamate receptor ligands in the patent literature

Potassium channel modulators for neurological disorders developed at Bristol-Myers Squibb

Noncardiotoxic anthracyclines disclosed by Gem

New anticoagulants/antithrombotics revealed by Zeneca

Potent, selective human beta3-AR agonist characterized by Merck & Co.

Highly potent and selective Y1 receptor antagonists designed at Lilly

Potent, orally active glucagon antagonist developed at Merck & Co.

Ibex implements major changes in new phase III study of Neutralase

Cytel halts clinical trials of Cylexin; company to focus on Epimmune's vaccine programs

Prosorba Column now available in U.S. for treatment of rheumatoid arthritis

Celgene and NCI collaborate on thalidomide cancer trial

FDA approves DepoCyt for treatment of lymphomatous meningitis

Targeted Genetics reports findings of gene therapy trial in cystic fibrosis

Terms of NeuroCell transfer proposal detailed by Genzyme Tissue Repair

Tasosartan provides effective control of essential hypertension in 10-week study

Zeneca files sNDA for change in dosing for Zestril

CAT and Wyeth-Ayerst initiate broad-based target validation and product development collaboration

Regeneron and P&G initiate diabetes-associated obesity trial of Axokine

FDA approval granted for BioTime's blood plasma volume expander

M-Vax cancer vaccine granted orphan drug designation

All rights to INFeD return to Schein

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...